DEA WEIGHS VIRTUAL PRESCRIBING — Opioid treatment advocates are closely watching the DEA as its telehealth rulemaking process forges ahead, and some are raising concerns. Under pandemic rules, providers could prescribe controlled substances, including treatments for opioid use disorder like buprenorphine, without an in-person visit. But with the end of the public health emergency in May, the DEA has been developing a post-pandemic policy. In February, the agency proposed limiting telemedicine prescribing of buprenorphine to a 30-day initial supply. But after backlash from treatment advocates, the agency extended pandemic rules through at least November. The latest: This month, the DEA said it would hold two in-person listening sessions in September on whether it should create a special registration process to allow providers to prescribe controlled substances without an in-person visit. Congress called for the DEA to create such a process in a 2008 law, but the agency hasn’t done so. A DEA official previously told POLITICO it didn’t do so in earlier regulations over concerns it could create additional burdens. The X-factor: Before Congress eliminated the so-called X-waiver in December, providers wanting to prescribe buprenorphine had to undergo a time-consuming process. Libby Jones, project director of the Overdose Prevention Initiative, fears that a special registration process could present similar barriers to the X-waiver by adding another hoop for providers to jump through, reducing potential prescribers. Dr. Brian Hurley, president of the American Society of Addiction Medicine, said that special registration would be counterproductive. Advocates for the broader telemedicine community have applauded DEA’s openness to special registration. But it’s still not clear exactly what special registration would look like. Ankit Gupta, CEO of telemedicine firm Bicycle Health, said special registration “should lean towards expanded access … with necessary safeguards, without the mandate of an in-person examination.” Mark Parrino, president of the American Association for the Treatment of Opioid Dependence, called for the DEA not to further regulate certified opioid treatment programs’ telemedicine use beyond Substance Abuse and Mental Health Services Administration proposals. What’s next: The DEA’s extension runs out in November for new patients, so it must act quickly to finalize a rule. Zoe Barnard, senior adviser at Manatt Health, says to expect legal challenges if the DEA restricts access to important drugs. WELCOME TO WEDNESDAY PULSE. What do you make of Biden’s mental health parity proposal? Is it workable? I want to hear from you — reach out at bleonard@politico.com. And send me or Chelsea (ccirruzzo@politico.com) your feedback, tips and scoops. Follow along @_BenLeonard and @ChelseaCirruzzo. TODAY ON OUR PULSE CHECK PODCAST, host Alice Miranda Ollstein talks with Lauren Gardner, who sorts through HHS' motion to dismiss a lawsuit by the U.S. Chamber of Commerce challenging the agency's new-found authority to negotiate drug prices through Medicare and the legal challenges facing the Biden administration's efforts to lower drug costs.
|